Clinical Trial Update: A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 study comparing brigatinib with alectinib in adults with ALK-positive non-small cell lung cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)
• Alunbrig (Brigatinib)

Snippet

Sponsor: Takeda | Conditions: ALK+ Advanced NSCLC | Phase 3 | Status: COMPLETED | Results posted: 2025-02-19